These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26154003)

  • 21. The Biosimilar Pipeline Seams Seem To Be Bursting.
    Reinke T
    Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
    Kirkner RM
    Manag Care; 2019 Jan; 28(1):5-6. PubMed ID: 30883313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Development. Are trade secrets delaying biosimilars?
    Price WN; Rai AK
    Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034
    [No Abstract]   [Full Text] [Related]  

  • 25. Statistical methods for assessing interchangeability of biosimilars.
    Chow SC; Yang LY; Starr A; Chiu ST
    Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Europe offers example for approving biosimilars.
    Carroll J
    Manag Care; 2013 Sep; 22(9):4-5. PubMed ID: 24167835
    [No Abstract]   [Full Text] [Related]  

  • 27. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
    Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
    Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights of biosimilars through SWOT analysis.
    Patel MM; Shah PJ; Patel BM
    Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
    [No Abstract]   [Full Text] [Related]  

  • 30. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 31. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First biosimilar drug approved for sale in the United States.
    Hede K
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444
    [No Abstract]   [Full Text] [Related]  

  • 33. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
    Bridges SL; White DW; Worthing AB; Gravallese EM; O'Dell JR; Nola K; Kay J; Cohen SB;
    Arthritis Rheumatol; 2018 Mar; 70(3):334-344. PubMed ID: 29411547
    [No Abstract]   [Full Text] [Related]  

  • 36. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?
    Carter AW
    J Diabetes Sci Technol; 2016 Sep; 10(5):1188-91. PubMed ID: 26817993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 10 years of biosimilars: lessons and trends.
    Royzman I; Shah K
    Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic Medicines Under the Microscope.
    Cauchi R
    State Legis; 2015; 41(7):12. PubMed ID: 26245000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.